JP2011522792A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011522792A5 JP2011522792A5 JP2011507897A JP2011507897A JP2011522792A5 JP 2011522792 A5 JP2011522792 A5 JP 2011522792A5 JP 2011507897 A JP2011507897 A JP 2011507897A JP 2011507897 A JP2011507897 A JP 2011507897A JP 2011522792 A5 JP2011522792 A5 JP 2011522792A5
- Authority
- JP
- Japan
- Prior art keywords
- poly
- particulate carrier
- carrier according
- agent
- polymer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003795 chemical substances by application Substances 0.000 claims 12
- 239000012867 bioactive agent Substances 0.000 claims 9
- 229920000642 polymer Polymers 0.000 claims 9
- 108090000623 proteins and genes Proteins 0.000 claims 8
- 102000004169 proteins and genes Human genes 0.000 claims 8
- 239000008346 aqueous phase Substances 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 239000012074 organic phase Substances 0.000 claims 6
- -1 poly (vinyl halide Chemical class 0.000 claims 5
- 229920002730 Poly(butyl cyanoacrylate) Polymers 0.000 claims 3
- 150000001450 anions Chemical class 0.000 claims 3
- 150000001768 cations Chemical group 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 239000000839 emulsion Substances 0.000 claims 3
- 239000010419 fine particle Substances 0.000 claims 3
- 239000000178 monomer Substances 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 claims 2
- 229920001710 Polyorthoester Polymers 0.000 claims 2
- 206010064930 age-related macular degeneration Diseases 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 229920001577 copolymer Polymers 0.000 claims 2
- PSLWZOIUBRXAQW-UHFFFAOYSA-M dimethyl(dioctadecyl)azanium;bromide Chemical group [Br-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC PSLWZOIUBRXAQW-UHFFFAOYSA-M 0.000 claims 2
- 230000002209 hydrophobic effect Effects 0.000 claims 2
- 150000002500 ions Chemical class 0.000 claims 2
- 239000002745 poly(ortho ester) Substances 0.000 claims 2
- 229920001610 polycaprolactone Polymers 0.000 claims 2
- 239000004632 polycaprolactone Substances 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 229920002554 vinyl polymer Polymers 0.000 claims 2
- KSXTUUUQYQYKCR-LQDDAWAPSA-M 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KSXTUUUQYQYKCR-LQDDAWAPSA-M 0.000 claims 1
- KGIGUEBEKRSTEW-UHFFFAOYSA-N 2-vinylpyridine Chemical compound C=CC1=CC=CC=N1 KGIGUEBEKRSTEW-UHFFFAOYSA-N 0.000 claims 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims 1
- 206010055665 Corneal neovascularisation Diseases 0.000 claims 1
- 229920001651 Cyanoacrylate Polymers 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- 229920002845 Poly(methacrylic acid) Polymers 0.000 claims 1
- 229920002732 Polyanhydride Polymers 0.000 claims 1
- 229920002125 Sokalan® Polymers 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- QYKIQEUNHZKYBP-UHFFFAOYSA-N Vinyl ether Chemical class C=COC=C QYKIQEUNHZKYBP-UHFFFAOYSA-N 0.000 claims 1
- 208000000208 Wet Macular Degeneration Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 150000008064 anhydrides Chemical class 0.000 claims 1
- 125000000129 anionic group Chemical group 0.000 claims 1
- 230000000975 bioactive effect Effects 0.000 claims 1
- 125000002091 cationic group Chemical group 0.000 claims 1
- 229960000800 cetrimonium bromide Drugs 0.000 claims 1
- 201000000159 corneal neovascularization Diseases 0.000 claims 1
- 150000001993 dienes Chemical class 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 208000030533 eye disease Diseases 0.000 claims 1
- 150000001261 hydroxy acids Chemical class 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 239000011859 microparticle Substances 0.000 claims 1
- 239000004005 microsphere Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- DDBRXOJCLVGHLX-UHFFFAOYSA-N n,n-dimethylmethanamine;propane Chemical compound CCC.CN(C)C DDBRXOJCLVGHLX-UHFFFAOYSA-N 0.000 claims 1
- 239000003960 organic solvent Substances 0.000 claims 1
- UCUUFSAXZMGPGH-UHFFFAOYSA-N penta-1,4-dien-3-one Chemical compound C=CC(=O)C=C UCUUFSAXZMGPGH-UHFFFAOYSA-N 0.000 claims 1
- 239000012071 phase Substances 0.000 claims 1
- 229920000771 poly (alkylcyanoacrylate) Polymers 0.000 claims 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims 1
- 229920000058 polyacrylate Polymers 0.000 claims 1
- 229920002647 polyamide Polymers 0.000 claims 1
- 229920002959 polymer blend Polymers 0.000 claims 1
- 229920000193 polymethacrylate Polymers 0.000 claims 1
- 229920000098 polyolefin Polymers 0.000 claims 1
- 229920002223 polystyrene Polymers 0.000 claims 1
- 229920002635 polyurethane Polymers 0.000 claims 1
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 210000001957 retinal vein Anatomy 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- KKEYFWRCBNTPAC-UHFFFAOYSA-L terephthalate(2-) Chemical compound [O-]C(=O)C1=CC=C(C([O-])=O)C=C1 KKEYFWRCBNTPAC-UHFFFAOYSA-L 0.000 claims 1
- 229920001567 vinyl ester resin Polymers 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5077508P | 2008-05-06 | 2008-05-06 | |
| US61/050,775 | 2008-05-06 | ||
| US7417108P | 2008-06-20 | 2008-06-20 | |
| US61/074,171 | 2008-06-20 | ||
| PCT/EP2009/055436 WO2009135853A2 (en) | 2008-05-06 | 2009-05-05 | Encapsulation of biologically active agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011522792A JP2011522792A (ja) | 2011-08-04 |
| JP2011522792A5 true JP2011522792A5 (enExample) | 2012-06-07 |
Family
ID=40944671
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011507897A Pending JP2011522792A (ja) | 2008-05-06 | 2009-05-05 | 生物活性薬の封入 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20110064821A1 (enExample) |
| EP (2) | EP2271323A2 (enExample) |
| JP (1) | JP2011522792A (enExample) |
| KR (3) | KR20110010760A (enExample) |
| AR (4) | AR071633A1 (enExample) |
| CA (1) | CA2721241A1 (enExample) |
| CL (4) | CL2009001076A1 (enExample) |
| PE (4) | PE20091829A1 (enExample) |
| TW (4) | TW201012490A (enExample) |
| UY (4) | UY31807A (enExample) |
| WO (1) | WO2009135853A2 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110064819A1 (en) * | 2008-05-06 | 2011-03-17 | Andrew Beaton | Encapsulation of biologically active agents |
| US9504759B2 (en) | 2011-08-11 | 2016-11-29 | Bar-Ilan University | Surface modified proteinaceous spherical particles and uses thereof |
| US10112988B2 (en) | 2012-01-09 | 2018-10-30 | Icb International, Inc. | Methods of assessing amyloid-beta peptides in the central nervous system by blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an anti-amyloid-beta peptide |
| US10112987B2 (en) * | 2012-01-09 | 2018-10-30 | Icb International, Inc. | Blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an amyloid-beta peptide |
| WO2015181344A1 (en) * | 2014-05-30 | 2015-12-03 | AbbVie Deutschland GmbH & Co. KG | Nanoencapsulation of antigen-binding molecules |
| US20170189344A1 (en) * | 2014-05-30 | 2017-07-06 | AbbVie Deutschland GmbH & Co. KG | Highly drug-loaded poly(alkyl 2-cyanoacrylate) nanocapsules |
| EP3154524B1 (en) * | 2014-06-12 | 2021-12-15 | Adare Pharmaceuticals USA, Inc. | Extended-release drug delivery compositions |
| EP4299058A3 (en) | 2014-06-24 | 2024-03-27 | The Trustees of Princeton University | Process for encapsulating soluble biologics, therapeutics, and imaging agents |
| WO2019055539A1 (en) | 2017-09-12 | 2019-03-21 | Prudhomme Robert K | CELLULOSIC POLYMER NANOPARTICLES AND METHODS OF FORMING THE SAME |
| US12357582B2 (en) * | 2017-11-03 | 2025-07-15 | The Trustees Of Princeton University | Hydrophobic ion pairing and flash nanoprecipitation for formation of controlled-release nanocarrier formulations |
| WO2020018890A1 (en) | 2018-07-19 | 2020-01-23 | Prudhomme Robert K | Triblock copolymer stabilizers for the formation of nanoparticles encapsulating soluble biologics, therapeutics, and imaging agents |
| US11731099B2 (en) | 2018-07-20 | 2023-08-22 | The Trustees Of Princeton University | Method for controlling encapsulation efficiency and burst release of water soluble molecules from nanoparticles and microparticles produced by inverse flash nanoprecipitation |
| US20220031630A1 (en) * | 2018-09-13 | 2022-02-03 | The Brigham And Women's Hospital, Inc. | Nanoparticle formulations and methods of their use |
| US20200147032A1 (en) | 2018-11-14 | 2020-05-14 | Robert K. Prud'homme | Dihydromyricetin hot melt extrusion formulations and methods for forming them |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4833666A (en) | 1986-12-24 | 1989-05-23 | U.S. Philips Corporation | Disc-record player suitable for scanning disc of different types |
| FR2649321A1 (fr) * | 1989-07-07 | 1991-01-11 | Inst Nat Sante Rech Med | Compositions a base de derives nucleotidiques, leurs procedes de preparation, et leurs utilisations notamment en tant que compositions pharmaceutiques |
| FR2659554B1 (fr) * | 1990-03-16 | 1994-09-30 | Oreal | Composition pour le traitement cosmetique et/ou pharmaceutique des couches superieures de l'epiderme par application topique sur la peau et procede de preparation correspondant. |
| AU3462193A (en) * | 1993-02-15 | 1994-08-29 | Shield Research Limited | Polyalkylcyanoacrylate nanocapsules |
| ATE197124T1 (de) * | 1993-09-09 | 2000-11-15 | Schering Ag | Wirkstoffe und gas enthaltende mikropartikel |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| GB9809839D0 (en) | 1998-05-09 | 1998-07-08 | Glaxo Group Ltd | Antibody |
| IL127127A0 (en) | 1998-11-18 | 1999-09-22 | Peptor Ltd | Small functional units of antibody heavy chain variable regions |
| US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| US7115396B2 (en) | 1998-12-10 | 2006-10-03 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| US20030152636A1 (en) * | 2000-02-23 | 2003-08-14 | Nanopharm Ag | Method of treating cancer |
| JP5291279B2 (ja) | 2000-09-08 | 2013-09-18 | ウニヴェルジテート・チューリッヒ | 反復モジュールを含む反復タンパク質の集合体 |
| CA2452382A1 (en) * | 2001-07-10 | 2003-01-23 | Corixa Corporation | Compositions and methods for delivery of proteins and adjuvants encapsulated in microspheres |
| TWI323265B (en) | 2002-08-06 | 2010-04-11 | Glaxo Group Ltd | Antibodies |
| EP1641818B1 (en) | 2003-07-04 | 2008-12-03 | Affibody AB | Polypeptides having binding affinity for her2 |
| WO2005019255A1 (en) | 2003-08-25 | 2005-03-03 | Pieris Proteolab Ag | Muteins of tear lipocalin |
| WO2005056764A2 (en) | 2003-12-05 | 2005-06-23 | Compound Therapeutics, Inc. | Inhibitors of type 2 vascular endothelial growth factor receptors |
| ES2318531T3 (es) | 2004-09-14 | 2009-05-01 | Nanodel Technologies Gmbh | Vehiculo de administracion que contiene nanoparticulas. |
| GB0525662D0 (en) | 2005-12-16 | 2006-01-25 | Glaxo Group Ltd | Immunoglobulins |
| DK2177536T3 (da) | 2006-03-30 | 2014-07-14 | Glaxo Group Ltd | Antistoffer mod amyloid-beta-peptid |
| EP1958957A1 (en) | 2007-02-16 | 2008-08-20 | NascaCell Technologies AG | Polypeptide comprising a knottin protein moiety |
| NZ580530A (en) | 2007-06-06 | 2012-04-27 | Domantis Ltd | Anti vegf polypeptides, antibody variable domains and antagonists |
| GB0724331D0 (en) | 2007-12-13 | 2008-01-23 | Domantis Ltd | Compositions for pulmonary delivery |
-
2009
- 2009-05-05 UY UY0001031807A patent/UY31807A/es unknown
- 2009-05-05 PE PE2009000607A patent/PE20091829A1/es not_active Application Discontinuation
- 2009-05-05 CL CL2009001076A patent/CL2009001076A1/es unknown
- 2009-05-05 UY UY0001031808A patent/UY31808A/es unknown
- 2009-05-05 PE PE2009000609A patent/PE20091965A1/es not_active Application Discontinuation
- 2009-05-05 WO PCT/EP2009/055436 patent/WO2009135853A2/en not_active Ceased
- 2009-05-05 CL CL2009001077A patent/CL2009001077A1/es unknown
- 2009-05-05 CL CL2009001081A patent/CL2009001081A1/es unknown
- 2009-05-05 KR KR1020107027449A patent/KR20110010760A/ko not_active Withdrawn
- 2009-05-05 TW TW098114865A patent/TW201012490A/zh unknown
- 2009-05-05 PE PE2009000606A patent/PE20091882A1/es not_active Application Discontinuation
- 2009-05-05 AR ARP090101616A patent/AR071633A1/es not_active Application Discontinuation
- 2009-05-05 PE PE2009000608A patent/PE20091964A1/es not_active Application Discontinuation
- 2009-05-05 AR ARP090101617A patent/AR072359A1/es not_active Application Discontinuation
- 2009-05-05 EP EP09742071A patent/EP2271323A2/en not_active Withdrawn
- 2009-05-05 TW TW098114853A patent/TW201012489A/zh unknown
- 2009-05-05 KR KR1020107027240A patent/KR20110010758A/ko not_active Withdrawn
- 2009-05-05 UY UY0001031809A patent/UY31809A/es unknown
- 2009-05-05 AR ARP090101619A patent/AR072668A1/es not_active Application Discontinuation
- 2009-05-05 AR ARP090101618A patent/AR071634A1/es not_active Application Discontinuation
- 2009-05-05 US US12/991,556 patent/US20110064821A1/en not_active Abandoned
- 2009-05-05 CA CA2721241A patent/CA2721241A1/en not_active Abandoned
- 2009-05-05 JP JP2011507897A patent/JP2011522792A/ja active Pending
- 2009-05-05 TW TW098114867A patent/TW201006495A/zh unknown
- 2009-05-05 UY UY0001031810A patent/UY31810A/es unknown
- 2009-05-05 EP EP11192165A patent/EP2441447A1/en not_active Withdrawn
- 2009-05-05 TW TW098114851A patent/TW201012488A/zh unknown
- 2009-05-05 KR KR1020107027425A patent/KR20110015604A/ko not_active Withdrawn
- 2009-05-05 CL CL2009001080A patent/CL2009001080A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Schopf et al. | Topical ocular drug delivery to the back of the eye by mucus-penetrating particles | |
| Yavuz et al. | In vitro/in vivo evaluation of dexamethasone—PAMAM dendrimer complexes for retinal drug delivery | |
| Sun et al. | Sustained release of brimonidine from a new composite drug delivery system for treatment of glaucoma | |
| Li et al. | Controlled release of bevacizumab through nanospheres for extended treatment of age-related macular degeneration | |
| Schnichels et al. | Self-assembled DNA nanoparticles loaded with travoprost for glaucoma-treatment | |
| Adibkia et al. | Inhibition of endotoxin-induced uveitis by methylprednisolone acetate nanosuspension in rabbits | |
| JP2017537985A5 (enExample) | ||
| Chennamaneni et al. | Development of a novel bioerodible dexamethasone implant for uveitis and postoperative cataract inflammation | |
| Shi et al. | RNA nanoparticle distribution and clearance in the eye after subconjunctival injection with and without thermosensitive hydrogels | |
| Feng et al. | Ocular Delivery of pRNA Nanoparticles: Distribution and Clearance After Subconjunctival Injection: Feng et al. | |
| JP2017061467A5 (enExample) | ||
| AU2019202037A1 (en) | Sunitinib formulations and methods for use thereof in treatment of ocular disorders | |
| Ghafoorianfar et al. | Efficiency of nanoparticles for treatment of ocular infections: Systematic literature review | |
| JP2016521712A5 (enExample) | ||
| EP2790733A2 (en) | Nanoparticles with enhanced mucosal penetration or decreased inflammation | |
| CN106572968A (zh) | 用于治疗眼科疾病和障碍的化合物 | |
| Cai et al. | Recent development of polymer nanomicelles in the treatment of eye diseases | |
| WO2004050060A1 (ja) | 結膜下デポによるドラッグデリバリーシステム | |
| Güven et al. | Olopatadine hydrochloride loaded Kollidon® SR nanoparticles for ocular delivery: Nanosuspension formulation and in vitro–in vivo evaluation | |
| Pita-Thomas et al. | Nanotechnology and glaucoma: little particles for a big disease | |
| JP2017527600A5 (enExample) | ||
| KR20130007531A (ko) | 유리체강내 주입을 위한 방법, 장치, 및 조성물 | |
| RU2017112930A (ru) | Офтальмологические составы для доставки лекарств и защиты переднего отдела глаза | |
| JP6749962B2 (ja) | 網脈絡膜障害の抑制剤 | |
| JP6249584B2 (ja) | 薬物含有徐放性微粒子の製造方法 |